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Cellular protein degradation pathways can be utilized by viruses to establish an environment that favors their
propagation. Here we report that the Kaposi’s sarcoma–associated herpesvirus (KSHV)-encoded latency-associated
nuclear antigen (LANA) directly functions as a component of the EC5S ubiquitin complex targeting the tumor
suppressors von Hippel-Lindau (VHL) and p53 for degradation. We have characterized a suppressor of cytokine
signaling box-like motif within LANA composed of an Elongin B and C box and a Cullin box, which is spatially located at
its amino and carboxyl termini. This motif is necessary for LANA interaction with the Cul5–Elongin BC complex, to
promote polyubiquitylation of cellular substrates VHL and p53 in vitro via its amino- and carboxyl-terminal binding
domain, respectively. In transfected cells as well as KSHV-infected B lymphoma cells, LANA expression stimulates
degradation of VHL and p53. Additionally, specific RNA interference–mediated LANA knockdown stabilized VHL and
p53 in primary effusion lymphoma cells. Thus, manipulation of tumor suppressors by LANA potentially provides a
favorable environment for progression of KSHV-infected tumor cells.
Citation: Cai QL, Knight JS, Verma SC, Zald P, Robertson ES (2006) EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor
suppressors. PLoS Pathog 2(10): e116. DOI: 10.1371/journal.ppat.0020116
Introduction
Kaposi’s sarcoma–associated herpesvirus (KSHV) is a DNA
tumor virus of the rhadinovirus subfamily associated with
rare endothelial and lymphoid cancers which was ﬁrst
discovered in Kaposi’s sarcoma (KS) lesions in 1994 [1]. It is
also tightly linked to other lymphoproliferative disorders
including primary effusion lymphoma (PEL) and multicentric
Castleman’s disease [2,3]. The rate of KS disease is increased
by immunosuppression in both organ transplant patients and
AIDS patients [4]. The KSHV-encoded latency-associated
nuclear antigen (LANA) is initially identiﬁed as a DNA
binding, nuclear transcription factor that also contributes to
KSHV latent replication by maintaining the viral episome
and is also involved in regulation of latency [5–8]. LANA
targets downstream viral promoters through both direct DNA
binding [9,10] and formation of protein complexes with at
least four other cellular DNA binding transcription factors:
CREB, CBP, Sp1, and STAT3 [11–15]. LANA also interacts
physically with a number of cellular proteins, such as p53,
pRB, and GSK3b, resulting in inhibition of p53-mediated
apoptosis, chromosome instability, derepression of Rb-tran-
scriptional activities, and dysregulation of b-catenin and the
Wnt signaling pathway [16–19].
Protein ubiquitylation is important for regulation of a
range of cellular processes in eukaryotes, including signal
transduction, development, apoptosis, cell cycle progression,
endocytosis, and immune response [20–22]. Many pathogens
such as HPV (E6 deregulates p53) and HIV (Vif targets
APOBEC3G) [23,24] have evolved numerous strategies to
control protein degradation by mimicking, blocking, or
redirecting the activity of the ubiquitin system [25]. In the
ubiquitin proteolytic pathways, there are two distinct steps as
follows: the covalent attachment of multiple ubiquitin
molecules to the protein substrate and the degradation of
the ubiquitylated protein by the 26S proteasome complex
[22]. The system responsible for ubiquitin attachment consists
of several components that act in concert. Using ATP as a
substrate, a ubiquitin-activating enzyme E1 (i.e., Uba1)
catalyzes the formation of a thioester bond between itself
and ubiquitin and then transfers the activated ubiquitin to a
ubiquitin-conjugating enzyme E2 (i.e., Ubc5a), which together
with a ubiquitin-protein ligase E3 or not speciﬁcally transfers
ubiquitin to the target protein [21,26,27]. The E3 ligase is
generally thought to be a group of multisubunit complexes
which are mostly responsible for substrate speciﬁc recog-
nition [21]. To date, this group consists of a superfamily of E3
ligase complex including the following: (1) SCF (Skp1-Cul1-F-
box)—in this complex, Skp1 links the scaffold protein Cullin
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box protein (b-TrCP) [28]; (2) ECS (Elongin C–Cul2/5-SOCS
[suppressors of cytokine signaling]-box) complex, in which
Elongin C bridges Cul2 or Cul5 to the SOCS-box–containing
adaptor protein (SOCS and VHL) [29,30]; (3) BC3B (BTB-
Cul3-BTB), in which the Skp1 and Elongin C structurally
homologous protein BTB interacts with Cul3 to degrade
target substrates (MEL-26) [31–34]; and (4) APC/C (APC2-C)
E3 ligase complex, which probably using Cul4 protein as a
scaffold [35,36]. Interestingly, in KSHV, the viral K3 and K5
proteins identiﬁed as PHD domain–containing E3 ubiquitin
ligases enrich this superfamily [37–40].
Hypoxia-inducible factor 1a (HIF-1a) is a subunit of the
heterodimer HIF-1 transcription factor that speciﬁcally
responds to hypoxia and activates a set of genes known to
be involved in angiogenesis, cell proliferation, survival, and
glucose metabolism [41–43]. In normoxia, HIF-1a is targeted
for ubiquitylation and degradation by both the tumor
suppressor von Hippel-Lindau (VHL) as a component of the
EC2S E3 ubiquitin ligase [29] and p53-associated Mdm2 as an
SCF E3 ligase [44]. Previous studies have shown that the
transcriptional activity of HIF-1a is increased not only by
intratumoral hypoxia but also by genetic alterations and loss
of function of cellular regulators including VHL and p53
[29,44].
In this report, we investigated the mechanisms by which the
KSHV encoded LANA targets the HIF-1a suppressors VHL
and p53 for degradation. LANA recruits the ubiquitin-
proteasome pathway resulting in a powerful inhibitory effect
on VHL- and p53-mediated HIF-1a degradation. The mech-
anism that involves binding to and targeting VHL and p53 for
degradation is mediated by an unconventional intrinsic
ubiquitin E3 ligase activity encoded by the SOCS-box–like
motif of LANA. These results imply that this ubiquitin-
proteasome pathway regulates normal VHL and p53 turnover
and show that their destabilizations are greatly enhanced by
interaction with LANA. This can contribute to a disruption of
the induced antiviral state during the KSHV latent infection.
Results
Identification of LANA as an Elongin BC Interacting
Protein
Previously, to identify binding partners for KSHV-encoded
latent protein LANA, a yeast two-hybrid screen was
performed using LANA as bait, together with a cDNA library
from human endothelial cells. One cDNA identiﬁed in this
screen was found to encode Elongin C. Since Elongin C has
been shown to directly bind to BC-box containing proteins
which usually interact with Elongin B and C complex (Elongin
Figure 1. LANA Associates with the Elongin BC Complex
(A) The amino-terminal domain of LANA directly interacts with Elongin C
but not Elongin B in vitro. The cDNA encoding N (1–340 aa), C (762-1162
aa), or NC (1–327^929-1162 aa) truncation of LANA with myc tagged
were expressed in a coupled transcription/translation system in the
presence of [
35S]methionine. Aliquots (20 ll) of the translation products
were pulled down by GST, GST–Elongin C, or GST–Elongin B, respectively.
The pulldown complex as well as a 1-ll aliquot of the transcription/
translation reaction (Input) were fractionated by SDS-PAGE, and detected
by a PhosphorImager. The proteins of GST and GST fused with Elongin B
or Elongin C were shown by Coomassie staining in the right panel.
(B) Elongin C is critical for LANA binding to Elongin B. In vitro produced
and [
35S]-labeled proteins LANA N (1–340 aa), Elongin C, and Elongin B
were incubated with anti-myc antibodies. The interacting complexes
were resolved by SDS-PAGE and examined by a PhosphorImager.
(C) LANA associates with Elongin BC complex in KSHV-infected cells. Cell
lysates of BCBL-1, DG-75, BJAB, or BJAB with KSHV infection (K-BJAB)
were subjected to IP against LANA or Elongin C (Elo. C) followed by IB
against LANA, Elongin C, and Elongin B (Elo. B).
DOI: 10.1371/journal.ppat.0020116.g001
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Synopsis
Ubiquitin is a small 8.5-kDa polypeptide with 76 amino acids which
is highly conserved in eukaryotes. Cellular proteins destined for
degradation are covalently linked to ubiquitin by a process called
ubiquitylation. This highly regulated process controls a broad range
of fundamental cellular functions, including signal transduction,
development, and apoptosis. Many pathogens invade host cells by
mimicking, blocking, or redirecting the activity of the cellular
ubiquitin system. Understanding the unique biological functions
targeted by these pathogens is a key goal in developing strategies
for prevention and protection against their invasions. This report
describes a unique functional role of the latency-associated nuclear
antigen (LANA) encoded by Kaposi’s sarcoma–associated herpesvi-
rus, a large DNA virus that persists in primary effusion lymphoma
and multicentric Castleman’s disease. LANA can modulate hypoxia-
inducible factor 1a activities by down-regulation of the critical
tumor suppressors von Hippel-Lindau (VHL) and p53 in B lymphoma
cells. In this pathway, LANA directly mimics and serves as an adaptor
molecule for a specific E3 ubiquitin complex through an unconven-
tional protein motif, to stimulate the ubiquitylation and degradation
of both VHL and p53. This is of fundamental importance because it
raises the interesting question as to whether this process is linked to
regulation of infection and pathogenesis by tumor viruses
associated with human cancers.BC), the association of LANA with Elongin C in yeast is likely
to also involve Elongin B. To conﬁrm the binding results from
the yeast two-hybrid screen, we examined in vitro binding
assays of Elongin BC to LANA. In in vitro translated [
35S]-
labeled methionine, different truncated forms (N: 1–340
amino acids [aa], C: 762-1162 aa, and NC: 1–327^929-1162 aa)
of LANA with myc tag were incubated with glutathione S-
transferase (GST)-fused Elongin B (Elo. B) or Elongin C (Elo.
C) beads. As shown in Figure 1A, LANA did not bind Elongin
B, whereas it clearly bound to Elongin C. Moreover, the
amino-terminal domain of LANA predominantly interacted
with Elongin C. This was further conﬁrmed by reverse
immunoprecipitation (IP) using a myc-tagged LANA N
truncated polypeptide (Figure 1B, lanes 5 and 6). In further
experiments, association between LANA and the Elongin BC
complex was assessed in co-IP experiments. Interestingly,
Elongin B efﬁciently precipitated with the amino-terminal
domain of LANA only when incubated along with Elongin C
(Figure 1B, compare lanes 6 and 7).
To speciﬁcally address the question as to whether or not
LANA does associate with the Elongin BC complex in KSHV-
infected cells, co-IP assays were done in PEL cells positive for
KSHV as well as an isogenic set of BJAB cell lines with and
without KSHV infection. The results of this assay nicely
showed that LANA associates with Elongin B as well as
Elongin C in the PEL cell line BCBL-1 as well as in a KSHV-
infected BJAB cell line (Figure 1C). This suggests that LANA
does exist in complex with Elongin BC in KSHV-positive cells.
The LANA/Elongin BC Complex Interacted with a Cul5/
Rbx1 Module
The Elongin BC complex was shown to be involved in
ubiquitylation as a component of the ECS E3 complex. To
determine whether the Elongin BC complex could function as
an adaptor which links LANA to a Cullin/Rbx1 module, thus
reconstituting an E3 ubiquitin ligase complex, IP assays
against myc tag were performed on lysates of Saos-2 cells
cotransfected with hemagglutinin (HA)-Rbx1 and HA-Cullin
(Cul2 or Cul5) in the presence or absence of myc-tagged
LANA expression vectors (Figure 2A). The results showed that
LANA did not associate with the Cul2/Rbx1module. However,
LANA did assemble with the Cul5/Rbx1 module (Figure 2A).
Further experiments with or without Elongin BC coexpres-
sion demonstrated that LANA–Elongin BC complex did
assemble with the Cul5/Rbx1 module to reconstitute a
multiprotein complex containing LANA, Elongin BC, Rbx1,
and Cul5 (Figure 2B) and the Elongin BC complex can
increase the afﬁnity of LANA interaction with Cul5 and Rbx1
module (Figure 2B).
The SOCS-Box–Like Motif Is Essential for LANA Association
with Cul5–Elongin BC Complex
A well-known family of Elongin BC–interacting proteins,
including VHL tumor suppressor and SOCS proteins, has
been recently identiﬁed as SOCS-box proteins [30]. These
proteins directly interact with Elongin BC through their
conserved BC-box motif [(A/P/S/T)L-x3-C-x3-(A/I/L/V)] and
associate with Cullin proteins through the conserved Cul-
box motif [UxxLPxP] [30]. Moreover, the two Cul boxes, the
Cul2 box and the Cul5 box, are speciﬁc for distinguishing
binding with the different Cullin proteins (Cul2 or Cul5). To
determine whether LANA interacts with Elongin BC and the
Cullin protein through its SOCS-box motif, we ﬁrst aligned
the sequence of LANA with VHL and SOCS (1, 2, and 3)
proteins. Our analysis showed that LANA probably also
contains an SOCS-box–like motif based on the hydrophobic
homology of consensus sequences. However, the BC box and
Cul box in this viral SOCS-box motif are atypical as
distinguished from the BC box which is usually close to the
Cul box found in SOCS-box motifs of cellular proteins. In
KSHV LANA these motifs were separately located from each
other in the amino-terminal and the carboxyl-terminal
domains. Furthermore, in contrast to the VHL Cul2 box
and SOCS protein Cul5 box, the LANA Cul box was
signiﬁcantly similar to the Cul box of the SOCS protein
family. This supports the evidence of LANA associated with
Cul5, not Cul2, protein in the IP assay above. Additionally,
the ORF73 homolog of LANA encoded by other gammaher-
pesvirus, including the rhesus monkey rhadinovirus (RRV) or
herpesvirus saimiri (HVS A11 and C488), also contains a
similar SOCS-box–like motif (Figure 3A).
To conﬁrm that LANA associates with Elongin BC and
Cullin 5 protein through its BC-box and Cul box motif, the
corresponding site-speciﬁc mutation and deletion of the
LANA SOCS-box–like motifs were generated. Co-IP assays
using different LANA mutants showed that the BC-box motif
deletion mutant resulted in a failure of LANA to bind with
the Elongin BC complex (Figure 3B). Additionally, LANA
Figure 2. The LANA–Elongin BC Complex Assemble with the Cul5/Rbx1 Module
(A) LANA protein associates with the Cul5/Rbx1 module but not Cul2/Rbx1 module, and (B) Elongin BC complex increases interaction of LANA with the
Cul5/Roc1 module. Saos-2 cells were transfected with expression vector encoding the indicated proteins in the figure. The lysates underwent IP using
anti-myc antibodies. Crude extracts (left panels) and immune complexes (right panels) were separated by SDS-PAGE and IB with the indicated
antibodies.
DOI: 10.1371/journal.ppat.0020116.g002
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LANA Targets VHL and p53 for DegradationFigure 3. LANA Associates with the Elongin BC Complex and Cul5 through the SOCS-Box–Like Motif
(A) KSHV LANA contains a putative SOCS-box motif which includes a consensus of BC-box and Cul-box motifs. Upper panels show hydrophobic
sequence alignment of the BC-box and Cul-box motifs from viral LANA and cellular SOCS-box–containing proteins that bind Elongin BC and Cullin
proteins individually. Conserved residues with similarity are shaded in the upper panel. Lower panels show ORF73 proteins from other
gammaherpesvirus contain an SOCS-box–like motif which is similar to KSHV LANA. HVS, herpesvirus saimiri; RRV, rhesus monkey rhadinovirus. The site
mutations of LANA in leucine (L) and/or cystine (C) are indicated with underlining.
(B) LANA associates with the Elongin BC complex through the BC-box motif. Saos-2 cells were transfected with expression vector encoding the
indicated proteins. The WT LANA and its mutant with BC-box (DBC) deletion and point mutation (LPCF, L213G or C217G) within BC box were compared.
Since LANA lost its normally top bands (approximately 230 kDa) in the L213G mutant, another two lower bands of LANA (between 190 kDa and 230
kDa) were specifically present. The lysates underwent IP and IB assays as described previously. RD, relative density.
(C) LANA associates with Cullin 5 through the Cul-box motif. Saos-2 cells were transfected with expression vector encoding the indicated proteins. The
WT LANA with Cul-box (DCul) or SOCS-box (DSCOS) deletion was compared. The lysates underwent IP and IB assays as described previously. Crude
extracts (left panels) and immune complexes (right panels) are shown.
(D) LANA assembles with Elongin BC complex and Cul5/Rbx1 module to reconstitute a multiprotein complex with E3 ubiquitin ligase activity. Left panel
shows the LANA–Elongin BC–Cul5–Rbx1 complex had ubiquitin ligase activity. The cell lysates of WT LANA (Figure 3C, lane 4) or SOCS-box–like motif
deletion mutant (Figure 3C, lane 3) as control was subjected to anti-myc immunoaffinity purification. The purified LANA immune complex (IC) was
incubated with various combinations of Uba1 (E1), Ubc5a (E2), and GST-ubiquitin (GST-Ub) in the absence or presence of ATP, to assess its ability to
stimulate ubiquitylation in vitro. The proteins were separated by SDS-PAGE and IB using anti-GST antibodies. Right panel shows SOCS-box–like motif
deletion reduced the capacity of LANA to induce polyubiquitylation. Saos-2 cells were transfected with WT LANA or its SOCS mutant. After 24-h
transfection, cells were treated with MG132 (0.5 lM) for 2 h. Lysates were subjected to IB against Ub or myc antibodies.
DOI: 10.1371/journal.ppat.0020116.g003
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resulted in a decrease in the ability of LANA to bind to the
Elongin BC complex when compared with wild-type (WT)
LANA (Figure 3B). LANA binding with Cul5/Rbx1 module
and Elongin BC complex was completely disrupted when the
SOCS-box motif was deleted (Figure 3C). Cul5 is known to
interact with Elongin BC complex [24,30,45–47]. Thus, when
the LANA Cul-box motif deletion mutant was coexpressed
with Elongin BC and tested for binding to the Cul5/Rbx1
module and Elongin BC complex, we observed that the LANA
mutants with Cul5 box deletion had same remaining binding
activity to the Cul5/Rbx1 module and Elongin BC complex
(Figure 3C). To conﬁrm Cul-box motif is necessary for LANA
to speciﬁcally bind Cul5 protein, further experiments were
performed and demonstrated that LANA with the Cul-box
deleted lost binding to the Cul5 protein when assayed without
the Elongin BC complex coexpression (unpublished data).
Taken together, these data suggest that these motifs are
critical for LANA interaction with the Elongin BC/Cul5/Rbx1
module and indicate that BC-box motif and Cul-box motif
are likely to be in close proximity in terms of the spatial
structure of the LANA protein in order to constitute an
intact SOCS-box motif.
The LANA–Elongin BC Complex Is Capable of Assembling
with Cul5/Rbx1 Module to Reconstitute an E3 Ubiquitin
Ligase
To investigate whether the LANA–Elongin BC–Cul5–Rbx1
complex possesses ubiquitin ligase activity, the complex was
immunoafﬁnity puriﬁed and assayed for its ability to activate
formation of polyubiquitin chains by the E2 ubiquitin–
conjugating enzyme Ubc5a in the presence of ATP, the E1
ubiquitin–activating enzyme Uba1, and GST-ubiquitin. As
shown in Figure 3D, the LANA–Elongin BC–Cul5–Rbx1
complex stimulated formation of a ladder suggesting poly-
ubiquitylation of the GST-ubiquitin, whereas the LANA
SOCS-box mutant did not (Figure 3D, left panel, lanes 6
and 7). As expected, formation of polyubiquitin conjugates
depended on the presence of the E1 ubiquitin–activating
enzyme, E2 ubiquitin–conjugating enzyme, and ATP (Figure
3D). In addition, in vivo proteasome inhibitor assays further
showed that WT LANA was capable of signiﬁcantly enhancing
polyubiquitylation activities when compared to that of the
LANA DSOCS mutant (Figure 3D, right panel, lanes 2 and 3).
Elongin BC Binding Increases Stability of LANA Expressed
in Cells
During our studies, we observed that the levels of WT
LANA coexpressed with Elongin BC were consistently
increased. Therefore, to determine whether this increase in
levels of WT LANA could be attributed at least in part to
potential stabilization of LANA by Elongin BC, WT LANA or
the SOCS-box–like motif deletion mutant (DSOCS) was
transiently expressed in Saos-2 cells with or without Elongin
BC. Twenty-four hours after transfection, cyclohexamide was
added to cultures to block further protein synthesis, and the
rate of decay of WT and mutant LANA protein was measured
by Western blot analysis. The results showed that the level of
WT LANA protein remained constant for at least 24 h after
treatment of cyclohexamide to cells cotransfected with LANA
along with Elongin BC (Figure 4A, left panel, and 4B).
However, in the absence of cotransfected Elongin BC when
an SOCS-box deletion mutant of LANA was used, almost 50%
of the LANA protein was lost within 5 h. Thus, WT LANA
protein exhibits increased stability when coexpressed with
Elongin BC (Figure 4A, right panel, and 4B). In contrast to
Figure 4. Binding to the Elongin BC Complex Stabilizes LANA
(A) The stabilities of WT LANA and its SOCS motif mutant. Five million
Saos-2 cells were transfected with 5 lg of LANA-WT (left panel) or LANA-
DSOCS (right panel) expression vector in the presence of 5 lg of Elongin
B and 5 lg of Elongin C expression vectors, as indicated. Twenty-four
hours after transfection, cells were treated with 100 lg/ml cyclo-
hexamide (CHX) for different times (0, 5, 10, and 24 h). Aliquots (40 lg) of
each whole-cell extract underwent IB with the indicated antibodies.
(B) The relative levels of WT LANA and its SOCS mutant coexpression
with Elongin BC complex. Protein density was quantitated by
densitometry of immunoblots using Odyssey Image v1.2 from three
separate experiments.
DOI: 10.1371/journal.ppat.0020116.g004
Figure 5. The Tumor Suppressors p53 and VHL Are Inhibited in the KSHV
Latently Infected and LANA-Expressing Cells
(A) IB analysis of KSHV-positive cell lines (BC-3, BCBL-1, JSC-1, and BC-1)
and KSHV-negative cell lines (BJAB, DG-75, and Louckes) against p53,
VHL, and b-actin. Ten million of each cell line were lysed and
coimmunoprecipitated using anti-VHL antibodies followed by detection
with anti-VHL. Cell lysate (5%) was used in IB assays with anti-p53 and
anti–b-actin. The data show that p53 and VHL in KSHV-positive cells are
more strongly inhibited than in KSHV-negative cells.
(B) The levels of p53 and VHL protein in B-lymphoma cells with KSHV
latent infection. Ten million BJAB- or KSHV-infected BJAB (k-BJAB) cells
were lysed and coimmunoprecipitated using anti-VHL antibodies
followed by detection with anti-VHL. Cell lysate (5%) was used in IB
assays against LANA, p53, and b-actin. The data showed that the tumor
suppressor proteins p53 and VHL were inhibited during KSHV infection.
(C) p53 and VHL are inhibited in the LANA stable expressing cells. Ten
million 293/LANA or 293/Vector stable cell lysates were analyzed by IB
against LANA, p53, and VHL as described previously. The data showed
that LANA decreases tumor suppressor p53 and VHL levels.
(D) p53 and VHL turnover in the LANA knockdown BCBL-1 cells. Cell
lysates from stable BCBL-1 cells with LANA or control firefly luciferase
knockdown (RNAi) were subjected to IB assays (left panel) against LANA,
p53, VHL, and b-actin, or total RNA underwent RT-PCR analysis (right
panel). RD, relative density.
DOI: 10.1371/journal.ppat.0020116.g005
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instability in the presence or absence of cotransfected
Elongin BC (unpublished data), suggesting a requirement
for the SOCS-box–like motif of LANA for enhanced stability.
Levels of the Tumor Suppressors p53 and VHL Are
Significantly Reduced in LANA-Expressing Cells
To determine the effect of LANA on targeted protein
degradation, we examined the endogenous levels of some
cellular tumor suppressors (such as p53 and VHL) expression
in KSHV-positive (BCBL-1, JSC-1, BC-3, and BC-1) and
-negative (BJAB, Louckes, and DG75) cell lines. Similar to
previous studies which showed that p53 protein expression
was decreased in KSHV-positive cells [17], our Western blot
analysis of four KSHV-positive PEL cell lines showed that p53
levels were signiﬁcantly reduced compared to KSHV-negative
B cell lines (Figure 5A). Additionally, the levels of the HIF-1a–
suppressor protein VHL were also reduced in KSHV-positive
cells (Figure 5A). To avoid the inconsistency of genotype
among different cell lines, we also compared the levels of p53
and VHL in cell lines with the same genotypic background
BJAB and KSHV-infected BJAB. The resulting data further
conﬁrmed that levels of the tumor suppressor proteins p53
and VHL did dramatically reduce after the KSHV infection
(Figure 5B). To determine that the results for both p53 and
VHL inhibition was associated with LANA, stable 293 cell
lines expressing LANA were generated. Similar results of
tumor suppressor p53 and VHL inhibition by LANA were
observed when immunoblotting (IB) assays were performed
(Figure 5C). To further conﬁrm the role of LANA on p53 and
VHL inhibition, LANA in the KSHV-positive BCBL-1 cell line
was knocked down by the introduction of small interference
RNA speciﬁcally against LANA. Again, analysis using IB assays
showed that the tumor suppressors p53 and VHL were greatly
rescued on inhibition of LANA expression (Figure 5D, left
panel). Furthermore, no obvious change was observed for p53
and VHL mRNA transcripts after LANA transcripts were
decreased, supporting the hypothesis that LANA can induce
the degradation of p53 and VHL proteins (Figure 5D, right
panel).
LANA Mediates the Degradation of p53 and VHL through
Ubiquitylation
We wanted to explore whether the potential mechanism
for LANA-mediated degradation of the tumor suppressors
p53 and VHL was related to LANA recruitment of the EC5S
ubiquitin E3 ligase complex. As p53 was shown to interact
with the carboxyl-terminal domain of LANA [17], we ﬁrst
determined the binding domain of LANA with VHL with in
vitro [
35S]-labeled methionine translated proteins using the
p53 protein as a positive control. The results of the in vitro
pulldown assays showed that distinct from LANA binding to
p53 through its carboxyl-terminal domain, the region of
LANA binding to VHL was located in the amino-terminal
domain using in vitro IP assays (Figure 6A). Supporting in
vivo IP assays further conﬁrmed that full-length LANA was
associated with the tumor suppressors p53 and VHL (Figure
6B).
To determine the extent of the involvement of LANA
recruitment of the EC5S E3 ligase for degradation of p53 and
VHL, we utilized the speciﬁc SOCS-box mutant of LANA
which lacks association with the EC5S complex. The con-
structs expressing p53, HA-ubiquitin (Ub), and WT LANA or
its SOCS-deleted mutant were cotransfected into Saos-2 cells.
Figure 6. Distinct Domains of LANA Interact with Tumor Suppressors p53 and VHL
(A) The amino-terminal domain of LANA binding VHL and carboxyl-terminal domain binding p53 in vitro. The cDNA encoding N (1–340 aa), C (762-1162
aa), and NC (1–327^929-1162 aa) LANA with myc tag, HA-VHL, and p53 were translated in a coupled transcription/translation system in the presence of
[
35S]methionine. Fifteen-microliter aliquots of the translation products were immunoprecipitated with anti-myc antibodies. Immunoprecipitated
proteins (IP) and a 1-ll aliquot of the transcription/translation reaction (Input) were fractionated by SDS-PAGE and detected by autoradiography. RD,
relative density.
(B) LANA is associated with p53 and VHL in cells. Saos-2 cells were cotransfected with expression vector encoding the indicated proteins. The lysates
underwent IP using anti-myc antibodies. Crude extracts (left panels) and immune complexes (right panels) were separated by SDS-PAGE and IB with
antibodies indicated. Asterisk indicates IgG heavy chain.
DOI: 10.1371/journal.ppat.0020116.g006
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LANA Targets VHL and p53 for DegradationThe Western blot data showed that ubiquitylation of p53 in
the presence of LANA was dramatically increased but
minimally so when the DSOCS mutant of LANA was coex-
pressed (Figure 7A, left panel, lanes 4 and 6). Similarly, WT
LANA also can induce VHL polyubiquitylation more efﬁ-
ciently when compared to the DSOCS mutant in VHL-
deﬁcient cell line 786-O (Figure 7A, right panel, lanes 10 and
12). Unexpectedly, the level of LANA could be seen to be
decreased when p53 was coexpressed (Figure 7A, compare
lane 5 with lanes 3 and 4) and slightly decreased when VHL
was coexpressed (Figure 7A, compare lane 11 with lanes 10
and 12). This indicated that although LANA can mediate
degradation of the tumor suppressors p53 and VHL through
interaction with its amino and carboxyl-terminal domains,
the tumor suppressors p53 and VHL are also likely to
contribute to regulation of LANA levels, as both are
components of two separate E3 ligase complex that may also
regulate LANA’s activity, and these activities may functionally
compete in virally infected cells [29,44].
To detect the speciﬁcity of LANA for targeting p53 and
VHL for degradation, in vitro, LANA–Elongin BC–Cul5
complex ubiquitylation assays were performed using puriﬁed
GST-p53 or GST-VHL as substrates. The results showed that
only WT LANA could speciﬁcally recruit ubiquitin complex
to induce GST-p53 or GST-VHL polyubiquitylation, but not
its SOCS-deleted mutant or vector control in this in vitro
assay (Figure 7B).
Aberrantly Expressed LANA Conquers p53 or VHL Function
as Components of E3 Ubiquitin Complexes Leading to
Their Degradation
As both p53 and VHL are components of two separate E3
ubiquitin complexes, we wanted to determine whether
aberrantly expressed LANA can conquer p53 and VHL
functions as components of E3 ubiquitin complex leading
to their degradation in KSHV-infected cells. We tested the
interaction of the tumor suppressor p53 or VHL with LANA
at different expression levels, as well as the effect on one of
their downstream effectors proteins, HIF-1a [29,44]. As
expression of LANA was increased without exogenous p53
or VHL coexpression, we found that LANA reduced levels of
p53 and VHL in a dose-dependent manner (Figure S1A and
S1B, right panels). As expected, when p53 was coexpressed
with LANA and HIF-1a with increasing concentrations of
p53, the levels of LANA as well as of HIF-1a levels were
reduced, which was similar to expression of p53 and HIF-1a
alone (Figure S1A, left panels). Similarly, increasing concen-
trations of VHL also inhibit LANA expression in a dose-
dependent manner (Figure S1B, left panels). To determine
the functional consequences of LANA on HIF-1a transcrip-
tional activities in the context of p53 and VHL, reporter
assays were performed using an HIF-1a response element
reporter in various cell lines. The reporter assays further
conﬁrmed that the transcriptional activity of HIF-1a was
strikingly reduced when p53 and VHL were cotransfected,
whereas increased levels of LANA coexpressed rescued HIF-
1a transcriptional activity most likely through targeting and
degrading the HIF-1a suppressors p53 and VHL (Figure S2).
Therefore, these results suggested that LANA expression is
involved in regulating the degradation of the tumor
suppressors p53 and VHL during KSHV-mediated onco-
genesis, thus inhibiting their suppressive effects on HIF-1a
transcriptional activities.
Discussion
In humans, targeting regulators of angiogenesis to protea-
some-mediated degradation in virus-infected cells is getting
increasing attention. The KSHV-encoded latent protein
LANA was originally identiﬁed as a major viral antigen
whose expression plays a crucial role in replication and
maintenance of the viral episomes in PEL cells [6,48–51].
Here we demonstrated that the KSHV-encoded LANA
protein interacts with the Elongin BC complex through the
binding of Elongin C to the LANA BC-box motif located
within its amino terminus. The LANA–Elongin BC complex
was capable of assembling with a Cullin/Rbx1 module to
reconstitute a multiprotein complex with ubiquitin ligase
activity. Furthermore, the facts that LANA only associated
with Cul5, and not with Cul2, and that a mutation in the Cul-
box motif of LANA at its carboxyl terminus abolished Cul5
binding in the absence of Elongin BC indicate that LANA can
directly interact with Cul5. Interaction of the Elongin BC
complex with the BC box markedly increased the stability of
LANA protein, suggesting that it may be necessary to protect
LANA from degradation in order to assemble the functional
E3 ubiquitin ligase complex, as previously proposed for
SOCS-box family proteins [52,53]. Thus, our results suggest
that LANA can recruit the Elongin BC complex and Cul5/Rbx
Figure 7. LANA Promotes Polyubiquitylation of Tumor Suppressors p53
and VHL
(A) LANA induces p53 and VHL polyubiquitylation. Saos-2 (left panel) or
786-O (right panel) cells were cotransfected with different combinations
of myc-LANA (WT and DSOCS), myc-p53 (or HA-VHL), and HA-Ub as
indicated. At 48 h posttransfection, transfected cells were harvested,
lysed, and protein normalized. Total protein (40 lg) was subjected to
resolve and IB assays against myc (LANA), p53 (or VHL), and b-actin. The
data showed LANA can induce p53 and VHL ubiquitylation in vivo.
(B) The LANA–Elongin BC–Cul5–Rbx1 complex induces p53 and VHL
polyubiquitylation in vitro. The cell lysates of WT LANA (Figure 3C, lane 4)
or SOCS-box–like motif deletion mutant (Figure 3C, lane 3) as control was
subjected to anti-myc immunoaffinity purification. The purified LANA
immune complex (IC) was incubated with various combinations of Uba1
(E1), Ubc5a (E2), His-Ub, or GST-VHL (or GST-p53) in the presence of ATP
in vitro. The proteins were separated by SDS-PAGE and IB against GST
antibody. Left panel, GST-p53; right panel, GST-VHL.
DOI: 10.1371/journal.ppat.0020116.g007
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LANA Targets VHL and p53 for Degradationmodule through its SOCS-box–like motif to function as an
EC5S ubiquitin ligase. Binding of the Elongin BC complex
served to stabilize LANA, and binding to Cul5 provided a
bridge to recruit Rbx1 and activate the ubiquitin-conjugating
process.
Ubiquitin conjugation to protein substrates is strictly
regulated by the speciﬁcity of the ubiquitin–protein E3 ligase
complex. Therefore, identiﬁcation of key regulators of
angiogenesis in human cancers targeted for proteasomal
degradation and mediated by KSHV-encoded LANA is highly
signiﬁcant. Previous evidence has shown that HIF-1a is a
critical regulator of numerous cellular growth factors and can
also function as a regulator of tumor angiogenesis, growth,
and metastasis and is commonly overexpressed in a number
of human cancers [43,54–56]. Recently, VHL and p53 have
been demonstrated to be involved in the regulation of HIF-1a
through ubiquitin-mediated degradation [29,44]. In this
study, we present data to show that the levels of the HIF-
1a–suppressor protein VHL were dramatically decreased in
KSHV-positive compared with KSHV-negative cells. Addi-
tionally, the tumor suppressor protein p53 was also signiﬁ-
cantly reduced in KSHV-infected cells as previously reported
[17]. The WT LANA, but not mutant deleted for the SOCS-
box motif, facilitated VHL and p53 ubiquitylation, suggesting
that LANA is involved in the degradation of these HIF-1a–
suppressor molecules and can function as an adaptor
molecule to the EC5S ubiquitin ligase complex which
contributes to the rescue of HIF-1a. These ﬁndings shed
light on the unique property of KSHV latently infected KS
lesions predominantly seen in the lower extremities in elderly
patients in whom oxygen is typically poor [57].
Interestingly, both Cul2 and Cul5 are known to be involved
in ECS-type E3 ubiquitin ligase complex. As to why LANA
preferentially associates with the Cul5 and not the Cul2
protein, our data suggest that the Cul-box motif as well as
additional sequences in the vicinity located in the carboxyl
terminus of LANA may be important in this selection process.
The Cul5–Elongin BC complex was shown to interact with a
number of SOCS-box–containing proteins, such as MUF1,
ASB2, and the SOCS family of proteins [45,47,58]. Although
the mechanism by which Cul5 functions in these processes
remains unclear, some viral proteins recruiting Cul5-con-
taining ECS ubiquitin ligase have been shown to regulate the
turnover of molecules involved in cell-cycle control, such as
adenovirus E4 orf6 [59] and the HIV vif-1 proteins [46]. Here
the interaction of LANA with Cul5 further emphasizes a role
for Cul5 in the regulation of virus-mediated dysregulation of
cell growth and oncogenesis.
A major difference between the SOCS-box motif of KSHV
LANA and the consensus SOCS-box sequence of cellular
proteins is the greater distance between the BC box and the
Cul box in this motif [30]. Our data strongly suggest that this
speciﬁc characteristic of the SOCS-box–like motif in ORF73
proteins encoded by other gammaherpesvirus is highly
conserved and that this structure allows LANA greater
ﬂexibility for interaction with the Elongin C and Cullin
proteins to achieve its function. The fact that LANA can bind
to VHL and p53 via its amino- and carboxyl-terminal
domains, respectively, inducing their degradation, is consis-
tent with this hypothesis (Figure 8).
It is noteworthy to mention that the cellular tumor
suppressors VHL and p53 can also inhibit the ability of the
viral protein LANA to regulate HIF-1a levels when they are
highly expressed, as they can also act as adaptors of EC2S–
and SCF–type E3 ligase complex, respectively. Thus, the
utilization of VHL-deﬁcient 786-O cells or p53-deﬁcient Saos-
2 cells was critical for clearly deﬁning the functional role of
LANA in the regulation of VHL and p53 [29,44]. This also
indicates that the balance between the cellular mechanisms
usurped by KSHV and the host cellular defense mechanisms
is critical for determination of cell fate. The higher levels of
LANA expression in KSHV-infected cells are likely to be
crucial to subdue the cellular defenses during KSHV
infection (Figure S3), and this is consistent with the fact that
LANA is highly expressed in KS and PEL cells [60–62].
This study reinforces the view that regulation of protein
degradation is an important mechanism for the control of
angiogenesis and oncogenesis during KSHV latent infection.
Materials and Methods
Plasmids, cell lines, and culture. Constructs expressing LANA full
length and its truncated LANA1–340 (N), LANA762-1162 (C), and
LANA1–327^929-1162 (NC) in the pA3M vector were described
previously [63]. Constructs expressing LANA with 212–222 aa (BC
box), 1085–1091 aa (Cul box), or 212–222^1085–1091 (SOCS box) aa
deletion or site mutation (L213G, C217G, and L213PC217F) in pA3M
were prepared by PCR mutagenesis. pA3M/p53 was constructed by
Jason S. Knight. GST-p53 was as described previously [64]. Plasmids
pCEP4/HIF-1a and pCEP4 were provided by Gregg L. Semenza (Johns
Hopkins University School of Medicine, Baltimore, Maryland, United
States). Plasmid pCMV/HA-VHL was provided by William G. Kaelin
(Howard Hughes Medical Institute, Chevy Chase, Maryland, United
States). Multimeric hypoxia response element (HRE) in pGL2-Basic
vector was a gift from Craig B. Thompson (University of Pennsylvania
Medical School, Philadelphia, Pennsylvania, United States). pcDNA3/
HA-Rbx1 was provided by Yue Xiong (University of Rochester
Lineberger Cancer Center, Rochester, New York, United States).
pcDNA3/HA-Ub was provided by George Mosialos (Alexander
Fleming Biomedical Sciences Research Center, Vari, Greece).
VR1012/HA-Cul2 and VR1012/HA-Cul5 were provided by Xiao-Fang
Yu (Johns Hopkins University School of Medicine). T7-Elongin B in
pcDNA3.1, His-HPC4-Elongin C in pcDNA3.1, GST-ubiquitin in
pGEX-4T-2, myc-Uba1-His in pET-23b, and His-hUbc5a-Flag in
pRSETB were provided by Joan W. Conaway (University of Kansas
Figure 8. A Model for KSHV LANA Assembles EC5S Ubiquitin Complex to
Target Downstream Substrates for Degradation
LANA is predicted to form a complex with Cul5/Rbx1 that interacts with
Elongin BC but not LANA DSOCS (Cul box and BC box) mutant. LANA
acts as adapter to link substrates which bind at its amino (1) or carboxyl
(2) -terminal domain (like VHL and p53)t oE C 5S ubiquitin complex and
induces the pathway of ubiquitin E1 activation, E2 conjugation, and
substrate polyubiquitylation as well as 26S proteasome–mediated
degradation.
DOI: 10.1371/journal.ppat.0020116.g008
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LANA Targets VHL and p53 for DegradationMedical Center). GST-VHL (54–213) in pGEX-4T-3 was provided by
Bill Kaelin (Howard Hughes Medical Institute). Constructs HA–
Elongin B, HA–Elongin C, GST–Elongin B, and GST–Elongin C were
obtained from Elongin B and Elongin C PCR products cloned into
pcDNA-3HA and pGEX-2T vectors, respectively.
Renal carcinoma VHL-null cell line 786-O was kindly provided by
Volker H. Haase (University of Pennsylvania Medical School). Human
osteosarcoma p53-null cell line Saos-2 was obtained from Jon Aster
(Brigham and Women’s Hospital, Boston, Massachusetts, United
States). BJAB, DG75 and Louckes KSHV-negative type cells and BC-3,
BCBL-1, JSC-1 and BC-1 KSHV-positive type cells were maintained
in RPMI 1640 medium (Invitrogen, Carlsbad, California, United
States) with 7% FBS, 4 lM L-glutamine, penicillin, and streptomycin.
The other cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen) supplemented with 5% fetal bovine serum,
penicillin, and streptomycin. BJAB cells latently infected with KSHV
were kindly provided by Michael Lagunoff of the University of
Washington [65]. Human embryonic kidney (HEK) 293/pA3M-LANA
and 293/pA3M stable cell lines were selected by 1 lg/ml Puromycin.
Cells were transfected by electroporation with a Bio-Rad (Hercules,
California, United States) Gene Pulser in 0.4-cm cuvettes at 220 V
and 975 lF.
Antibodies, IB, and IP. The monoclonal antibodies mouse anti-HA
(12CA5) and mouse anti-myc (9E10) were purchased from Covance
Research Products (Denver, Pennsylvania, United States). Anti-
ubiquitin (FL-76) and anti-p53 (DO-1) were obtained from Santa
Cruz Biotechnology (Santa Cruz, California, United States). Mouse
anti–HIF-1a (BD Transduction Laboratory, San Jose, California,
United States), mouse anti-VHL (BD Transduction Laboratory),
mouse anti–Elongin B (BD Transduction Laboratory), mouse anti–
Elongin C (BioLegend, San Diego, United States), rabbit anti-GST
(Amersham Biosciences, Little Chalfont, United Kingdom), rabbit
anti-LANA polyclonal antibody (provided by Bala Chandran of
Rosalind Franklin University of Medicine and Science, North
Chicago, Illinois, United States), and anti–b-actin (Cell Signaling
Technology) were also used.
Twenty million whole-cell lysates were extracted in 200 llo f
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.6],
150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1 mM phenyl-
methylsulfonyl ﬂuoride, 1 lg/ml aprotinin, and 1 lg/ml pepstatin).
Protein concentration was determined by Bio-Rad protein assay.
Protein was separated by SDS-PAGE and transferred onto poly-
vinylidene ﬂuoride membranes. After blocking with 5% nonfat dry
milk in PBS (2 mM KCl, 120 mM NaCl, 1.5 mM KH2PO4,8m M
Na2HPO4) containing 0.1% Tween 20, proteins were probed with the
corresponding antibodies. For detection of proteins, appropriate
infrared-conjugated secondary antibodies (Alexa Fluor 800 or 680)
were used with the Li-COR (Lincoln, Nebraska, United States)
Odyssey scanner. For IP, after one-step preclearing (rotation 1 h, 4
8C) with protein A/G (50/50) Sepharose fast ﬂow (Amersham
Biosciences), antibodies were added to the cell protein extract in a
binding buffer adjusted to 20 mM Tris (pH 7.5), 200 mM NaCl, and
0.1% Nonidet P-40. After overnight incubation, immunocomplexes
were recovered with protein A/G (50/50) Sepharose for 1-h
incubation. After three washes with binding buffer, proteins were
eluted in sample buffer and resolved by SDS-PAGE electrophoresis.
RNA interference. siRNAs complementary to the C-terminal
(GCTAGGCCACAACACATCT) fragment of LANA as described
previously [16] were cloned into the pSIREN vector according to
the instruction of manufacture (Clontech, Palo Alto, California,
United States) to generate si-LANA construct. pSIREN vector with
luciferase target sequence was used as control. Ten million BCBL-1
cells were cotransfected by electroporation with 5 lg of si-LANA (or
si-Luc). BCBL-1 knockdown stable cells were selected and maintained
in 4 lg/ml puromycin.
Expression and puriﬁcation of recombinant proteins in Escherichia
coli. Overnight starter cultures (50 ml) of E. coli BL21 (DE3)
transformed with pGEX-4T-GST-ubiquitin, pGEX-2T-Elongin B,
pGEX-2T Elongin C, pET-23b-myc-Uba1-His, and pRSETB-His-
hUbc5a-Flag were incubated into 500 ml of culture medium and
grown at 30 8C to an optical density of about 0.6 at 600 nm. After
IPTG induction (0.5 mM, 2 h at 30 8C), bacteria were collected and
sonicated in lysis buffer containing 20 mM Tris-HCl (pH 8.0), 100 mM
NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 1 M DTT, 5% Sarkosyl, and
the protease inhibitor cocktail for use with mammalian cell extracts.
Uba1, Ubc5, and His-ubiquitin proteins were puriﬁed by Ni
2þ-NTA
agarose chromatography (Qiagen, Valencia, California, United
States), and GST-ubiquitin, GST–Elongin B, or GST–Elongin C was
puriﬁed by glutathione sepharose chromatography (Amersham
Biosciences) and then dialyzed against 40 mM HEPES-NaOH (pH
7.9), 60 mM potassium acetate, 1 mM MgCl2, 0.5 mM EDTA, 10%
glycerol, and 2 mM DTT.
Pulldown assays. T7 promoter fused cDNA for expressing
Elongin B, Elongin C, p53, VHL, or LANA derivatives was
incubated in the presence of [
35S]methionine for 3 h at 30 8C
according to the manufacturer’s instructions (Promega, Madison,
Wisconsin, United States). Translation products of 15 ll of each
protein were incubated with 1 ll of anti-myc (9E10) antibody (for
GST pulldown, incubated with GST, or GST-tagged recombinant
protein) in 500 ll of binding buffer (50 mM Tris-HCl [pH 7.5], 100
mM NaCl, 10 lM ZnCl2, 10% glycerol, freshly supplemented with 0.1
mM DTT and protease inhibitor) overnight at 4 8C. Proteins were
recovered with protein A/G (50/50) Sepharose for 1-h incubation.
After three washes with washing buffer (50 mM Tris-HCl [pH 7.5], 100
mM NaCl, 10 mM MgCl2, 5% glycerol, 0.1% Nonidet P-40, and 0.3
mM DTT with protease inhibitor), proteins were eluted in sample
buffer and resolved by SDS-PAGE and then autoradiographed and
scanned by a PhosphoImager (Amersham Biosciences).
Ubiquitylation assays. For ubiquitylation assays, cell extracts with
WT or mutant myc-tagged LANA expression were immunoprecipi-
tated with anti-myc antibody and protein A/G Sepharose fast ﬂow as
described previously [47]. After three washes with binding buffer and
two washes with a buffer containing 40 mM HEPES-NaOH (pH 7.9),
60 mM potassium acetate, 1 mM MgCl2, 0.5 mM EDTA, 10% glycerol,
and 2 mM DTT, the beads were mixed with 500 ng of Uba1, 1.4 lgo f
Ubc5a, and 2.5 lg of GST-ubiquitin or His-ubiquitin with 2.5 lg GST-
p53 (GST-VHL) in a 15-ll reaction containing 4 mM HEPES-NaOH
(pH 7.9), 6 mM potassium acetate, 5 mM MgCl2, 1 mM DTT, and 1.5
mM ATP. Reaction mixtures were incubated for 1 h at 30 8C. Reaction
products were fractionated by SDS-PAGE and analyzed by IB with
anti-GST antibody.
RT-PCR. RT-PCR was used to compare the mRNA levels of p53 or
VHL in BCBL-1 cells with LANA knockdown or without. Total RNA
was isolated by using TriZOL reagent (Invitrogen) following the
manufacturer’s protocol. RT-PCR was performed by using Super-
Script II RT kit (Invitrogen) following the manufacturer’s instruc-
tions. Brieﬂy, RT-PCR was done in a total volume of 20 ll containing
10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 200 lM concentration of
each deoxynucleotide triphosphate, 2 lM concentration of each
primer, 2 ll of randomly primed cDNA, and 0.5 unit of AmpliTaq
(Applied Biosystems, Foster City, California, United States. Primers
for desired gene (LANA, 59-ATGTGACTTCGCCAACCGTAG-39 and
59-TGCTTCTT CTGCAATCTCCG-39; p53, 59-CTCTCGGAA-
CATCTCGAAGC-39 and 59-GCG CACAGAGGAAGAGAATC-39;
VHL,5 9-GAAGAGTACGGCCCTGAA-39 and 59-GGCAGTGTGA-
TATTGGCA-39; GAPDH, 59-TGCACCACCAACTGCTTAG  39 and
59-GATGCAGGGATGATGTTC-39) were included in some PCRs
where indicated. PCR was done on an MJ Research Opticon II
thermocycler (Waltham, Massachusetts, United States) by ﬁrst heating
the reaction at 94 8C for 5 min and then cycling the reaction 35 times
with conditions set as 94 8C for 30 s, 50 8C for 30 s, and 72 8C for 30 s.
Five microliters of the ampliﬁcation products was analyzed by
electrophoresis on 2% agarose gel and visualized after staining with
ethidium bromide.
Luciferase reporter assays. Luciferase reporter assays were
performed after transient transfection of each construct as a reporter
plasmid by following the manufacturer’s protocol. Brieﬂy, at 48 h
posttransfection, 10 million transfected cells from each sample were
harvested and subsequently washed once with PBS (Invitrogen),
followed by lysis with 200 ll of reporter lysis buffer (Promega,
Madison, Wisconsin, United States). A 40-lg total protein of the lysate
was mixed with 100 ll of luciferase assay reagent. Luminescence was
measured by the OpticompI Luminometer (MGM Instruments,
Hamden, Connecticut, United States) for 10 s. Relative luciferase
activity was expressed as fold activation relative to the reporter
construct alone. The results shown represent experiments performed
in triplicate.
Supporting Information
Figure S1. Aberrant Expression of LANA Conquers p53 or VHL as a
Component of E3 Ubiquitin Complex for Degradation
Tumor suppressor p53 (A) and VHL (B) competes with LANA. 786-O
and Saos-2 cell lines were individually transfected with different
doses (0, 1, 5, 10 lg) of LANA or cotransfected HIF-1a (5 lg) with
different doses (0, 1, 5, 10 lg) of p53 (or VHL) in the presence or
absence of LANA (2 lg) as indicated. Cell lysates (40 lg) underwent IB
assays against myc (p53 or LANA), HA (VHL), and b-actin as described
previously. The data show that LANA can inhibit endogenous p53 or
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VHL also can inhibit LANA expression and further suppress HIF-1a.
Relative density (RD) of VHL, p53, and LANA protein was shown in
lower panels.
Found at DOI: 10.1371/journal.ppat.0020116.sg001 (92 KB PDF).
Figure S2. LANA Attenuates the Inhibition of p53 and VHL to
Regulate the Transcriptional Activities of HIF-1a
(A) BJAB, (B) 786-O, and (C) Saos-2 cells were cotransfected
individually as indicated (10 lg of LANA, 5 lgo fVHL, and 5 lgo f
p53). The multimeric hypoxia response element (HRE) promoter with
luciferase reporter was used to detect the transcriptional activity of
HIF-1a affected by VHL and p53. The transfected cell lysates
underwent luciferase reporter assay as described previously. The
data showed the LANA attenuates the inhibition of VHL or p53 to
HIF-1a to increase transcription of HRE-containing promoter. The
transcriptional activity of HIF-1a was expressed as the fold activation
relative to activity with responding reporter construct alone
(control). Means and standard deviations from three independent
experiments are shown.
Found at DOI: 10.1371/journal.ppat.0020116.sg002 (19 KB PDF).
Figure S3. Proposed Model for Viral Protein LANA Interacts with
Cellular Protein VHL and p53
During virus invasion, KSHV-encoded LANA is aberrantly expressed
and possesses cellular EC5S ubiquitin complex to induce tumor
suppressors VHL and p53 for degradation. In the other hand, the
housekeeper genes encoded proteins in host cells together perform
regular cellular mechanism, like VHL EC2S and p53 SCF ubiquitin
pathway, to defense against infection via inhibiting viral protein
expression.
Found at DOI: 10.1371/journal.ppat.0020116.sg003 (14 KB PDF).
Accession Numbers
The National Center for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov) accession numbers are KSHV (NC_003409),
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